CHECKPOINT-INHIBITOR TOXICITY
Immune-related adverse events
Indexed by organ, with every dose and threshold quoted from the chapter that states it — and every disagreement between societies left standing rather than resolved for you.
Each card is anchored on the society chapters this atlas holds for that organ — ASCO, ESMO and SITC, though not every organ has all three, and each page names its own. The supporting sentence is stored verbatim beside every dose, threshold and rate. Where a guideline states nothing, the card says so instead of filling the gap. Where sources genuinely disagree, every position is shown side by side, each labelled with what kind of source it is — a single centre’s protocol and a society guideline do not carry the same weight, and a grading vocabulary is neither.
This covers immune checkpoint inhibitors only — it is not a general anti-cancer toxicity reference. Educational reference, not medical advice.
Browse by organ
- Kidney1 entryAcute tubulointerstitial nephritis dominates; glomerular lesions and electrolyte disturbances are increasingly reported.ICI-associated acute tubulointerstitial nephritisOpen
- Gastrointestinal1 entryThe commonest serious ICI toxicity and the one most skewed to CTLA-4 blockade. Diarrhoea and colitis are not the same event and do not occur at the same rate — the gap between them is what decides whether steroids are indicated at all.ICI-associated diarrhoea and colitisOpen
- Liver1 entryUsually asymptomatic transaminase elevation found on pre-cycle bloods, most often in the first 6-12 weeks. Steroid-responsive, and the alternative causes of liver injury have to be excluded first.ICI-associated hepatitisOpen
- Lung1 entryPneumonitis, whose symptoms and imaging are non-specific enough that the work-up is largely one of exclusion — infection, tumour progression, embolism, cardiac causes — and which can be radiographically visible while the patient is asymptomatic.ICI-associated pneumonitisOpen
- Endocrine5 entriesHormone deficiency, not inflammation to be suppressed: thyroid dysfunction, hypophysitis, primary adrenal insufficiency and insulin-dependent diabetes, each with its own replacement.ICI-associated hypothyroidismICI-associated hyperthyroidismICI-associated hypophysitisICI-associated primary adrenal insufficiencyICI-associated insulin-dependent diabetesOpen
- Skin2 entriesThe commonest and usually the earliest irAEs — mostly inflammatory eruptions, pruritus and vitiligo, rarely a reason to stop the drug. Blisters, mucosal involvement or bullous formation are the finding that changes the pathway.ICI-associated inflammatory and bullous dermatoses, pruritus and vitiligoSevere cutaneous adverse reactions (SJS/TEN, DRESS, AGEP)Open
Educational use only. Educational synthesis of the published literature — not a treatment protocol, dosing guide, or medical advice. Regimens and agents shown are illustrative of what the literature describes; verify against current guidelines (ASON / KDIGO / ASCO / NCCN) and individualize to the patient. Using this site creates no clinician–patient relationship.
Spotted an error? Tell us. Sourcing and method are described on Methods.